FrancophonIA/ELRC3.0 huggingface dataset:
English: Infections and infestations Nasopharyngitis
Estonian: Infektsioonid ja infestatsioonid Nasofarüngiit
English: Each blister strip contains either 6 or 10 hard capsules.
Estonian: Igas blisterribas on kas 6 või 10 kõvakapslit.
English: In vitro inhibition studies demonstrated that glycopyrronium bromide has no relevant capacity to inhibit CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4/5, the efflux transporters MDR1, MRP2 or MXR, and the uptake transporters OCT1 or OCT2.
Estonian: In vitro uuringud näitasid, et glükopürrooniumbromiidil puudub oluline võime inhibeerida CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 või CYP3A4/5, väljavoolu transportsüsteeme MDR1, MRP2 või MXR ning sissevoolu transportsüsteeme OCT1 või OCT2.
English: If a dose is missed, the next dose should be taken as soon as possible.
Estonian: Kui annus jääb manustamata, tuleb järgmine annus manustada niipea kui võimalik.
English: If signs suggesting allergic reactions occur, in particular, angioedema (including difficulties in breathing or swallowing, swelling of the tongue, lips, and face), urticaria or skin rash, treatment should be discontinued immediately and alternative therapy instituted.
Estonian: Kui ilmnevad allergilisele reaktsioonile viitavad sümptomid, eriti angioödeem (sealhulgas hingamis- või neelamisraskused, keele, huulte ja näo turse), urtikaaria või nahalööve, tuleb ravi koheselt lõpetada ja alustada alternatiivset ravi.
English: In patients with COPD, pharmacokinetic steady-state of glycopyrronium was reached within one week of the start of treatment.
Estonian: KOKi haigetel saavutati glükopürrooniumi farmakokineetiline püsiseisund ühe nädala jooksul pärast ravi alustamist.
English: Reproduction studies and other data in animals do not indicate a concern regarding fertility in either males or females (see section 5.3).
Estonian: Reproduktsiooniuuringutest ja muud loomkatsetest saadud andmed ei viita fertiilsuse langusele meestel ega naistel (vt lõik 5.3).
English: Gastrointestinal effects including gastroenteritis and dyspepsia were also observed.
Estonian: Täheldati ka seedetrakti häireid, sh gastroenteriiti ja düspepsiat.
English: COPD exacerbation data was collected in the 6- and 12-month pivotal studies.
Estonian: KOKi ägenemiste andmed koguti 6 ja 12 kuud kestnud kesksetest uuringutest.
English: Adverse reactions reported during the first six months of two pooled pivotal Phase III trials of 6 and 12 months duration are listed by MedDRA system organ class (Table 1).
Estonian: Esimese kuue kuu jooksul teatatud kõrvaltoimed kahes 6- ja 12-kuud kestnud keskses III faasi uuringus on loetletud MedDRA organsüsteemi klasside järgi (tabel 1).
English: Dry mouth was reported mainly during the first 4 weeks of treatment with a median duration of four weeks in the majority of patients.
Estonian: Suukuivust kirjeldati põhiliselt esimesel neljal ravinädalal ning enamikel patsientidel kestis see keskmiselt neli nädalat.
English: 3H]-labelled glycopyrronium bromide to humans, the mean urinary excretion of radioactivity in 48 hours amounted to 85% of the dose.
Estonian: 3H]-märgistatud glükopürrooniumbromiidi veenisisest manustamist inimestele ulatus radioaktiivsuse keskmine eritumine uriiniga 48 tunni jooksul 85%-ni annusest.
English: High doses of glycopyrronium may lead to anticholinergic signs and symptoms for which symptomatic treatment may be indicated.
Estonian: Suured glükopürrooniumi annused võivad viia antikolinergiliste nähtude ja sümptomiteni, mis võivad vajada sümptomaatilist ravi.
English: How to store Tovanor Breezhaler Contents of the pack and other information
Estonian: Kuidas Tovanor Breezhalerit säilitada Pakendi sisu ja muu teave
English: Each pack contains a device called an inhaler, together with capsules in blisters.
Estonian: Igas pakendis on seade, mida nimetatakse inhalaatoriks, ja blistritesse pakendatud kapslid.
English: Tovanor Breezhaler once daily has also shown a statistically significant effect on health-related quality of life measured using the St. George's Respiratory Questionnaire (SGRQ).
Estonian: Üks kord ööpäevas manustatava Tovanor Breezhaleri puhul on näidatud ka statistiliselt olulist mõju tervisega seotud elukvaliteedile, mida hinnati SGRQ (St. George's Respiratory Questionnaire) küsimustiku põhjal.
English: • Tovanor Breezhaler capsules must always be stored in the blister card and only removed immediately before use.
Estonian: • Tovanor Breezhaleri kapsleid peab alati hoidma blisterpakendis ja eemaldama alles vahetult enne kasutamist.
English: Excipient(s) with known effect: Each capsule contains 23.6 mg lactose (as monohydrate).
Estonian: Teadaolevat toimet omav(ad) abiaine(d): Üks kapsel sisaldab 23,6 mg laktoosi (monohüdraadina).
English: What Tovanor Breezhaler looks like and contents of the pack Tovanor Breezhaler 44 micrograms inhalation powder, hard capsules are transparent and orange and contain a white powder.
Estonian: Kuidas Tovanor Breezhaler välja näeb ja pakendi sisu Tovanor Breezhaler 44 mikrogrammi inhalatsioonipulbri kõvakapslid on oranžid ja läbipaistvad ning sisaldavad valget pulbrit.
English: Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu
Estonian: Muud teabeallikad Täpne teave selle ravimi kohta on Euroopa Ravimiameti kodulehel: http://www.ema.europa.eu
English: The capsules must be administered only using the Tovanor Breezhaler inhaler (see section 6.6).
Estonian: Kapslite manustamiseks tohib kasutada ainult Tovanor Breezhaler inhalaatorit (vt lõik 6.6).
English: Hydroxylation resulting in a variety of mono-and bis-hydroxylated metabolites and direct hydrolysis resulting in the formation of a carboxylic acid derivative (M9) were seen.
Estonian: Hüdroksüülimise tulemusena moodustusid mitmesugused mono- ja bis-hüdroksüülitud metaboliidid ning otsese hüdrolüüsi tulemusena moodustus karboksüülhappe derivaat (M9).
English: A greater than 4-fold selectivity for the human M3 receptors over the human M2 receptor has been demonstrated using radioligand binding studies.
Estonian: Radioligandi seondumisuuringutes on demonstreeritud enam kui 4 korda suuremat selektiivsust inimese M3 kui M2 retseptorite suhtes.
English: The safety profile is further characterised by other symptoms related to the anticholinergic effects, including signs of urinary retention, which were uncommon.
Estonian: Ohutusprofiili iseloomustavad lisaks muud antikolinergilise toimega seotud sümptomid, sh uriinipeetuse nähud, mida esines aeg-ajalt.
English: During treatment with Tovanor Breezhaler, stop taking this medicine and tell your doctor immediately: - if you experience tightness of the chest, coughing, wheezing or breathlessness immediately after using Tovanor Breezhaler (signs of bronchospasm).
Estonian: Ravi ajal Tovanor Breezhaleriga, lõpetage selle ravimi kasutamine ning teavitage otsekohe oma arsti sellest: - kui teil tekib vahetult pärast Tovanor Breezhaleri kasutamist pingetunne rindkeres, köha, vilistav hingamine või hingeldus (bronhospasmi nähud).
English: However, glycopyrronium bromide (including its metabolites) was excreted in the milk of lactating rats (see section 5.3).
Estonian: Siiski eritus glükopürrooniumbromiid (kaasa arvatud selle metaboliidid) lakteerivate rottide piima (vt lõik 5.3).
English: About 90% of systemic exposure following inhalation is due to lung absorption and 10% is due to gastrointestinal absorption.
Estonian: Umbes 90% inhalatsioonijärgsest süsteemsest plasmatasemest on tingitud imendumisest kopsudes ja 10% imendumisest seedetraktis.
English: The absolute bioavailability of glycopyrromium inhaled via Tovanor Breezhaler was estimated to be about 45% of the delivered dose.
Estonian: Tovanor Breezhaleri kaudu inhaleeritud glükopürrooniumi absoluutne biosaadavus oli hinnanguliselt umbes 45%.
English: • Difficulty breathing with wheezing or coughing (signs of paradoxical bronchospasm)
Estonian: • Hingamisraskused koos viliseva hingamise või köhaga (paradoksaalse bronhospasmi nähud)
English: Patients should be informed about the signs and symptoms of acute narrow-angle glaucoma and should be informed to stop using Tovanor Breezhaler and to contact their doctor immediately should any of these signs or symptoms develop.
Estonian: Patsiente tuleb teavitada ägeda kitsa nurga glaukoomi sümptomitest ning juhendada, et ükskõik millise nimetatud sümptomi tekkimisel tuleb otsekohe lõpetada Tovanor Breezhaleri kasutamine ning võtta ühendust arstiga.
English: Elimination After intravenous administration of [
Estonian: Eritumine Pärast [
English: The recommended dose is the inhalation of the content of one capsule once daily using the Tovanor Breezhaler inhaler.
Estonian: Annustamine Soovitatav annus on ühe kapsli sisu inhalatsioon üks kord päevas Tovanor Breezhaler inhalaatorist.
English: What Tovanor Breezhaler is and what it is used for What you need to know before you use Tovanor Breezhaler How to use Tovanor Breezhaler Possible side effects
Estonian: Mis ravim on Tovanor Breezhaler ja milleks seda kasutatakse Mida on vaja teada enne Tovanor Breezhaleri kasutamist Kuidas Tovanor Breezhalerit kasutada Võimalikud kõrvaltoimed
English: • Painful and frequent urination
Estonian: • Valulik ja sagenenud urineerimine
English: Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucosegalactose malabsorption should not take this medicinal product.
Estonian: Patsiendid, kellel on harvaesinev pärilik galaktoositalumatus, laktaasipuudulikkus või glükoosigalaktoosi imendumishäire, ei tohi seda ravimit kasutada.
English: 1) More frequent for glycopyrronium than placebo in the 12 months database only.
Estonian: 1) Glükopürrooniumiga sagedasem kui platseeboga ainult 12-kuulises uuringus.
English: These may be signs of an acute attack of narrow-angle glaucoma.
Estonian: Need võivad olla ägeda kitsa nurga glaukoomi nähud.
English: The use of glycopyrronium by breast-feeding women should only be considered if the expected benefit to the woman is greater than any possible risk to the infant (see section 5.3).
Estonian: Glükopürrooniumi kasutamist imetamise ajal tuleb kaaluda ainult juhul, kui oodatav kasu naisele ületab võimalikud ohud lapsele (vt lõik 5.3).
English: 2) Reports have been received from post-approval marketing experience in association with the use of Tovanor Breezhaler.
Estonian: 2) Teated on kogutud turuletulekujärgselt seoses Tovanor Breezhaleri kasutamisega.
English: The values for FEV1 at the end of the dosing interval (24 h post dose) were similar between the first dose and those seen after 1 year of dosing.
Estonian: FEV1 väärtused manustamisintervalli lõpus (24 tundi pärast annuse manustamist) olid sarnased esimese annuse järgselt ja pärast 1 aasta kestnud ravi.
English: The long duration of action can be partly attributed to sustained concentrations of active substance in the lung as reflected by the prolonged terminal elimination half-life of glycopyrronium after inhalation via the Tovanor Breezhaler inhaler in contrast to the half life after intravenous administration (see section 5.2).
Estonian: Pikk toime kestus on osaliselt tingitud toimeaine püsivast kontsentratsioonist kopsudes, mida näitab glükopürrooniumi pikk terminaalne eliminatsiooni poolväärtusaeg pärast inhalatsiooni Tovanor Breezhaler inhalaatorist erinevalt veenisisese manustamise järgsest poolväärtusajast (vt lõik 5.2).
English: This includes medicines similar to Tovanor Breezhaler used for your lung disease, such as ipratropium, oxitropium or tiotropium (so called anticholinergics).
Estonian: See kehtib ka Tovanor Breezhaleriga sarnaste ravimite kohta, mida kasutatakse teie kopsuhaiguse raviks, nagu ipratroopium, oksitroopium või tiotroopium (niinimetatud antikolinergilised ravimid).
English: Glycopyrronium should only be used during pregnancy if the expected benefit to the patient justifies the potential risk to the foetus.
Estonian: Tovanor Breezhalerit tohib raseduse ajal kasutada ainult juhul, kui oodatav kasu patsiendile õigustab võimalikku riski lootele.
English: In clinical studies with Tovanor Breezhaler, paradoxical bronchospasm was not observed.
Estonian: Tovanor Breezhaleri kliinilistes uuringutes ei täheldatud paradoksaalset bronhospasmi.
English: The co-administration of Tovanor Breezhaler with other anticholinergic-containing medicinal products has not been studied and is therefore not recommended.
Estonian: Tovanor Breezhaleri manustamist koos teiste antikolinergilisi aineid sisaldavate ravimitega ei ole uuritud ning seetõttu ei ole koosmanustamine soovitatav.
English: The European Medicines Agency has waived the obligation to submit the results of studies with Tovanor Breezhaler in all subsets of the paediatric population in COPD (see section 4.2 for information on paediatric use).
Estonian: Euroopa Ravimiamet ei kohusta esitama Tovanor Breezhaleriga läbi viidud uuringute tulemusi laste kõikide alarühmade kohta KOKi korral (teave lastel kasutamise kohta: vt lõik 4.2).
English: How to inhale Tovanor Breezhaler - In this pack, you will find an inhaler and capsules (in blisters) that contain the medicine as inhalation powder.
Estonian: Kuidas Tovanor Breezhalerit sisse hingata - Sellest pakendist leiate inhalaatori ja kapslid (blistrites), mis sisaldavad ravimit inhaleeritava pulbrina.
English: Tovanor Breezhaler should be used with caution in patients with narrow-angle glaucoma or urinary retention.
Estonian: Tovanor Breezhalerit peab ettevaatlikult kasutama patsientidel, kellel esineb kitsa nurga glaukoom või uriinipeetus.
English: If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Estonian: Kui arst on teile öelnud, et te ei talu teatud suhkruid, peate te enne selle ravimi kasutamist konsulteerima arstiga.
English: 6 x 1 capsules + 1 inhaler 10 x 1 capsules + 1 inhaler 12 x 1 capsules + 1 inhaler 30 x 1 capsules + 1 inhaler
Estonian: 6 x1 kapslit + 1 inhalaator 10 x1 kapslit + 1 inhalaator 12 x1 kapslit + 1 inhalaator 30 x1 kapslit + 1 inhalaator
English: They have the product code “GPL50” printed in black above and a company logo ( ) printed in black below a black bar.
Estonian: Kapslitele on mustas kirjas trükitud toote kood „GPL50” musta joone kohale ja firma logo ( ) musta joone alla.
English: The elimination pattern suggests sustained lung absorption and/or transfer of glycopyrronium into the systemic circulation at and beyond 24 hours after inhalation.
Estonian: Eritumise mudel näitab püsivat imendumist kopsudes ja/või glükopürrooniumi üleminekut süsteemsesse vereringesse 24 ja enam tundi pärast inhalatsiooni.
English: Following oral inhalation using the Tovanor Breezhaler inhaler, glycopyrronium was rapidly absorbed and reached peak plasma levels at 5 minutes post dose.
Estonian: Pärast suukaudset inhalatsiooni Tovanor Breezhaler inhalaatorist imendus glükopürroonium kiiresti ja saavutas maksimaalse plasmakontsentratsiooni 5 minutit pärast annuse manustamist.
English: Transparent orange capsules containing a white powder, with the product code “GPL50” printed in black above and the company logo ( ) printed in black below a black bar.
Estonian: Valget pulbrit sisaldavad läbipaistvad oranžid kapslid, millele on mustas kirjas trükitud toote kood „GPL50” musta joone kohale ja firma logo ( ) musta joone alla.
English: A slight reduction in heart rate (mean difference over 24 h -2 bpm when compared to placebo), which is a known effect of low exposures to anticholinergic compounds in young healthy subjects, was observed.
Estonian: Täheldati südame löögisageduse vähest aeglustumist (keskmine erinevus 24 tunni jooksul -2 lööki minutis võrreldes platseeboga), mis on antikolinergiliste ühendite madala plasmakontsentratsiooni teadaolev toime noortel tervetel isikutel.
English: This medicine contains an active substance called glycopyrronium bromide.
Estonian: See ravim sisaldab toimeainet, mida nimetatakse glükopürrooniumbromiidiks.
English: Productive cough
Estonian: Produktiivne köha
English: These findings were similar to those seen in patients receiving tiotropium, 53.4% of whom responded with 1 point or greater improvement (p=0.009 compared to placebo).
Estonian: Need leiud olid sarnased tiotroopiumi saanud patsientidel täheldatuga, kellest 53,4% saavutasid skoori paranemise ühe või enama punkti võrra (p=0,009 võrreldes platseeboga).
English: Some elderly patients above 75 years of age experienced headache (frequency common) and urinary tract infection (frequency common).
Estonian: Mõnedel üle 75-aastastel eakatel patsientidel on tekkinud peavalu (sage) ja kuseteede infektsioon (sage).
English: Tovanor Breezhaler 44 micrograms once daily provided consistently statistically significant improvement in lung function (forced expiratory volume in one second, FEV1, forced vital capacity, FVC, and inspiratory capacity, IC) in a number of clinical studies.
Estonian: Tovanor Breezhaler 44 mikrogrammi üks kord ööpäevas viis mitmes kliinilises uuringus kopsufunktsiooni (ühe sekundi forsseeritud ekspiratoorne maht [FEV1], forsseeritud vitaalkapatsiteet [FVC] ja inspiratoorne kapatsiteet [IC]) püsivalt statistiliselt olulise paranemiseni.
English: In a 3-week study where exercise tolerance was tested via cycle ergometer at submaximal (80%) workload (submaximal exercise tolerance test), Tovanor Breezhaler, dosed in the morning, reduced dynamic hyperinflation and improved the length of time exercise could be maintained from the first dose onwards.
Estonian: 3-nädalases uuringus, kus koormustaluvust hinnati veloergomeetri abil submaksimaalsel (80%) koormusel (submaksimaalne koormustaluvuse test), vähenes hommikul manustatud Tovanor Breezhaleri toimel dünaamiline hüperinflatsioon ja paranes koormustaluvuse aeg alates esimesest annusest.
English: - if you experience difficulties in breathing or swallowing, swelling of the tongue, lips or face, skin rash, itching and hives (signs of allergic reaction).
Estonian: - kui teil tekivad hingamis- või neelamisraskused, keele, huulte või näo turse, nahalööve, sügelus ja nõgestõbi (allergilise reaktsiooni nähud).
English: The clinical Phase III development programme included two phase III studies: a 6-month placebo-controlled study and a 12-month placebo and active-controlled (open label tiotropium 18 micrograms once daily) study, both in patients with clinical diagnosis of moderate to severe COPD.
Estonian: III faasi kliiniliste uuringute programm sisaldas kahte III faasi uuringut: 6 kuud kestnud platseebokontrollitud uuringut ning 12 kuud kestnud platseebo ja aktiivse võrdlusravimiga (tiotroopium 18 mikrogrammi üks kord ööpäevas) kontrollitud avatud uuringut.
English: - When you start a new pack, use the new Tovanor Breezhaler inhaler that is supplied in the pack.
Estonian: - Kui alustate uue pakendi kasutamist, kasutage pakendis olevat uut Tovanor Breezhaler inhalaatorit.
English: Tovanor Breezhaler contains lactose
Estonian: Tovanor Breezhaler sisaldab laktoosi
English: Tovanor Breezhaler administered at 44 micrograms once daily statistically significantly reduced breathlessness as evaluated by the Transitional Dyspnoea Index (TDI).
Estonian: Tovanor Breezhaler 44 mikrogrammi üks kord ööpäevas vähendas statistiliselt oluliselt TDI (Transitional Dyspnoea Index) põhjal hinnatud hingeldust.
English: In phase III studies, bronchodilator effects were seen within 5 minutes after the first dose and were maintained over the 24-hour dosing interval from the first dose.
Estonian: III faasi uuringutes täheldati bronhe lõõgastavat toimet 5 minuti jooksul pärast esimese annuse manustamist ning see püsis 24 tunni jooksul pärast esimest annust.
English: • Do not use the Tovanor Breezhaler capsules with any other inhaler.
Estonian: • Ärge kasutage Tovanor Breezhaleri kapsleid üheski teises inhalaatoris.
English: What Tovanor Breezhaler contains - The active substance is glycopyrronium bromide.
Estonian: Mida Tovanor Breezhaler sisaldab - Toimeaine on glükopürrooniumbromiid.
English: Tovanor Breezhaler once daily statistically significantly reduced the use of rescue medication (salbutamol) by 0.46 puffs per day (p=0.005) over 26 weeks and by 0.37 puffs per day (p=0.039) over 52 weeks, compared to placebo for the 6- and 12-month studies, respectively.
Estonian: Tovanor Breezhaleri manustamisel üks kord ööpäevas vähenes statistiliselt oluliselt hooravimi (salbutamooli) kasutamine 0,46 inhalatsiooni võrra päevas (p=0,005) 26 nädala jooksul ja 0,37 inhalatsiooni võrra päevas (p=0,039) 52 nädala jooksul võrreldes platseeboga vastavalt 6 ja 12 kuud kestnud uuringutes.
English: • Rash, itching, hives, difficulty breathing or swallowing, dizziness (possible signs of allergic reaction)
Estonian: • Lööve, sügelus, nõgestõbi, hingamis- või neelamisraskus, pearinglus (allergilise reaktsiooni võimalikud nähud)
English: Component of a multipack.
Estonian: Multipakendi osa.
English: PA/Alu/PVC - Alu perforated unit-dose blister Packs containing 6x1, 10x1, 12x1 or 30x1 hard capsules, together with one inhaler.
Estonian: PA/Alu/PVC - Alu perforeeritud üheannuseline blister Pakend, mis sisaldab 6x1, 10x1, 12x1 või 30x1 kõvakapslit ja ühte inhalaatorit.
English: These include sympathomimetic bronchodilators, methylxanthines, and oral and inhaled steroids.
Estonian: Nendeks ravimiteks on sümpatomimeetilised bronhodilataatorid, metüülksantiinid ning suukaudsed ja inhaleeritavad kortikosteroidid.
English: Talk to your doctor before using Tovanor Breezhaler, if any of the following applies to you: - you have kidney problems.
Estonian: Enne Tovanor Breezhaleri kasutamist pidage nõu oma arstiga, kui midagi järgnevalt loetletust kehtib teie kohta: - kui teil on probleeme neerudega.
English: Tovanor Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Estonian: Tovanor Breezhaler on näidustatud kasutamiseks bronhe lõõgastava säilitusravina sümptomite leevendamiseks kroonilise obstruktiivse kopsuhaigusega (KOK) täiskasvanud patsientidel.
English: In COPD patients with mild and moderate renal impairment (estimated glomerular filtration rate, eGFR ≥30 ml/min/1.73 m2) Tovanor Breezhaler can be used at the recommended dose.
Estonian: Kerge ja keskmise raskusega neerukahjustusega (hinnanguline glomerulaarfiltratsiooni kiirus, eGFR ≥30 ml/min/1,73 m2) KOKi patsientidel võib Tovanor Breezhalerit kasutada soovitatavas annuses.
English: When to inhale Tovanor Breezhaler Use this medicine at the same time each day.
Estonian: Millal Tovanor Breezhalerit sisse hingata Kasutage seda ravimit iga päev samal kellaajal.
English: Based on the magnitude of these changes, no clinically relevant drug interaction is expected when glycopyrronium is co-administered with cimetidine or other inhibitors of organic cation transport.
Estonian: Nende muutuste ulatuse alusel ei ole glükopürrooniumi ja tsimetidiini või teiste OCT inhibiitorite koosmanustamisel kliiniliselt olulisi koostoimeid oodata.
English: Patients with unstable ischaemic heart disease, left ventricular failure, history of myocardial infarction, arrhythmia (excluding chronic stable atrial fibrillation), a history of long QT syndrome or whose QTc (Fridericia method) was prolonged (>450 ms for males or >470 ms for females) were excluded from the clinical trials, and therefore the experience in these patient groups is limited.
Estonian: Patsiendid, kellel on anamneesis kardiovaskulaarhaigusi Kliinilistesse uuringutesse ei kaasatud patsiente, kellel oli ebastabiilne südame isheemiatõbi, vasaku vatsakese puudulikkus, anamneesis müokardiinfarkt, arütmia (välja arvatud krooniline stabiilne kodade virvendus), anamneesis pikenenud QT sündroom või kellel oli (Friderica meetodil) QTc pikenenud (>450 ms meestel või >470 ms naistel).
English: Check capsule is empty
Estonian: Vaata, kas kapsel on tühi